Ethical Medicines Industry Group

What Ethical Medicines Industry Group does

Ethical Medicines Industry Group (EMIG) is a UK trade association founded in 2017 that represents the interests of life sciences companies operating in the British market, with formal engagement extending to European policy via the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). The organization reports over 250 member companies and approximately 1,500 individuals in its network, spanning pharmaceutical manufacturers of all sizes, Associate Members such as consultancies and service providers, and free non-paying members including patient charities, research policy organisations, and universities. EMIG holds formal representation seats on the Department of Health & Social Care (DHSC), Medicines and Healthcare products Regulatory Agency (MHRA), All Wales Therapeutics and Toxicology Centre (AWTTC), and the Scottish Medicines Consortium, while Chairman Leslie Galloway serves as Vice President of EUCOPE.

EMIG's core products and services center on a members-only online platform (platform.emig.org.uk) that provides a personalized dashboard with three functional areas: a Network for anonymous Q&A and directory search across 1,500 individuals, Events for registration and live session access, and a Resources library containing documents, videos, and podcasts. Beyond the platform, the association runs 14 Special Interest Groups (SIGs) covering Regulatory Affairs, Market Access, Medical Affairs, Compliance, Digital, Environmental Sustainability, Patient Engagement, Women in Pharma, and devolved nations (Scotland, Wales, Northern Ireland), meeting quarterly in both virtual and in-person formats. The flagship in-person engagement includes Quarterly Meetings attracting approximately 140 senior managers and directors, and the Annual Parliamentary Dinner attracting 160-180 attendees including politicians and stakeholders.

EMIG operates a subscription-based membership revenue model with annual billing, where full membership fees are not publicly disclosed and patient charities, research policy organisations, and universities receive complimentary membership. Go-to-market is relationship-led, with the Chairman personally handling membership enquiries and the organization recruiting through its website, LinkedIn, X (Twitter), Quarterly Meetings, the Annual Parliamentary Dinner, webinars, and SIG-led events. The association does not sell software products but rather delivers policy advocacy, regulatory navigation support, networking, and intelligence sharing through SIGs and events, primarily serving UK life sciences companies with secondary European exposure through EUCOPE.

Name

Ethical Medicines Industry Group

Legal name

Ethical Medicines Industry Group

Website

https://emig.org.uk

Company type

Private

Founded year

2017

Operating status

Operating

Short description

Ethical Medicines Industry Group (EMIG) is a UK trade association founded in 2017 representing 250+ life sciences companies and 1,500+ individuals, delivering policy advocacy, regulatory engagement, networking, and 14 Special Interest Groups via a members-only online platform.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Membership Fees: EMIG operates as a trade association with membership fees. Over 250 member companies and organisations pay for membership which includes access to networking platform, events, special interest groups, resources, and policy representation.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

EMIG is a UK trade association that provides membership services to life sciences and pharmaceutical companies. Its offering centres on government and regulatory advocacy (DHSC, MHRA, NICE, NHS), 14 Special Interest Groups covering regulatory, market access, compliance, medical affairs, and devolved nations, networking through an online member platform and in-person events, and policy representation at UK and European level via EUCOPE.

Product overview

EMIG is a multi-stakeholder network and trade association representing life sciences companies in the UK. The organization operates primarily through its EMIG Online Platform (a members-only portal with Network, Events, and Resources functionality) and provides membership services including advocacy, networking, policy development, and access to 13-14 Special Interest Groups. Key offerings include Quarterly Meetings (~140 attendees), an Annual Parliamentary Dinner, and VPAG support services. EMIG does not offer software products per se but rather membership-based association services.

Differentiator

Problem solved

Functional benefit

Products and services

• Membership Services Annual trade association membership for life sciences and pharmaceutical companies, providing collective representation with Government and regulators, networking through 14 Special Interest Groups, access to the EMIG platform, and policy development support.
• EMIG Online Platform A members-only online portal (platform.emig.org.uk) providing a personalised dashboard with anonymous Network Q&A and directory search, event registration and scheduling, and access to a resources library of documents, videos, and podcasts.
• Government and Regulatory Advocacy Industry voice representation with the UK Government (DHSC), MHRA, NICE, NHS, devolved-nation HTA bodies (AWTTC, SMC), and EUCOPE at European level, focused on improving patient access to innovative medicines.
• Special Interest Groups (SIGs) 14 topic-focused Special Interest Groups covering Compliance, Digital, Environmental Sustainability, Market Access, Medical Affairs, Regulatory Affairs, Patient Engagement, People & Culture, Women in Pharma, and devolved nations (Scotland, Wales, Northern Ireland), meeting 3-4 times annually to develop policy positions and enable networking among members.
• Quarterly Meetings In-person EMIG Quarterly Meetings attracting approximately 140 senior managers and directors, featuring prominent speakers on current industry issues such as AI in pharma and MHRA innovation policy.
• Annual Parliamentary Dinner Annual dinner held in central London attracting 160-180 attendees including politicians, stakeholders, and EMIG members, featuring political insight guest speakers relevant to life sciences policy.
• VPAG Support Services Guidance and advocacy related to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG), including the £400m Industry Investment Facility that supports clinical trials (75%), innovative HTA approaches (5%), and manufacturing (20%).

Named customers10 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and major.

• Department of Health & Social Care (DHSC)coreStrategic or Co-development PartnerEMIG works closely with the Department of Health & Social Care in London on issues such as medicines supply and pricing. DHSC is a ministerial department responsible for England's NHS, the health of the nation and access to medicines.
• Medicines and Healthcare products Regulatory Agency (MHRA)coreStrategic or Co-development PartnerEMIG works closely with the MHRA to ensure the prompt availability of new medicines to patients. The MHRA is responsible for ensuring that medicines and medical devices in the UK work and are acceptably safe.
• All Wales Therapeutics and Toxicology Centre (AWTTC)coreStrategic or Co-development PartnerAWTTC advise on new medicines to ensure they are used effectively and appropriately in Wales. EMIG has a seat on the AWTTC Committee and the AWTTC Therapeutic Development Assessment (TDA) Group.
• European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)coreStrategic or Co-development PartnerEUCOPE has been the voice of small and mid-sized pharmaceutical and biotech companies in Europe for the last 15 years. EMIG has been part of EUCOPE from the outset and Leslie Galloway is Vice President of the Board, providing close contact with European Parliament, European Commission, and European Medicines Agency (EMA).
• NICEcoreStrategic or Co-development PartnerEMIG works in partnership with NICE for health technology appraisals. The Market Access Group assists Members in their engagement with NICE Scientific Advice and the NICE Office for Market Access.
• NHScoreStrategic or Co-development PartnerEMIG works closely with the NHS to ensure the prompt availability of new medicines to patients. The NHS is represented in the Medicines and Medical Devices Access Steering Committee.
• Health Research Authority (HRA)majorStrategic or Co-development PartnerEMIG works in partnership with HRA for research and development policy alignment.
• Office for Life Sciences (OLS)coreStrategic or Co-development PartnerEMIG engages with the Office for Life Sciences, a UK Government department. OLS co-chairs the £400m Investment Facility Fund with ABPI.
• Association of the British Pharmaceutical Industry (ABPI)coreStrategic or Co-development PartnerABPI co-chairs the £400m Investment Facility Fund with OLS. The Fund supports clinical trials (75%), innovative HTA approaches (5%), and manufacturing (20%).
• Scottish Medicines Consortium (SMC)coreStrategic or Co-development PartnerEMIG has a representative on the Scottish Medicines Consortium User Group Forum. The Scotland Group works with SMC on HTA assessments for Scottish market access.
• Northern Ireland Department of HealthmajorStrategic or Co-development PartnerEMIG Northern Ireland Group provides engagement with the NHS and other stakeholders in Northern Ireland on health policy and medicines access.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Medicines Australia: Australia's peak industry body for innovative pharmaceutical companies. Closely comparable in structure — a national trade association representing innovator pharma with deep engagement in HTA (PBAC), PBS reimbursement, and TGA regulatory policy — providing a useful international analogue to EMIG's UK model.
• Irish Pharmaceutical Healthcare Association (IPHA): Ireland's representative body for the research-based pharmaceutical industry. Comparable trade association model focused on a single national market, engaging HTA, reimbursement, and regulatory counterparts (HSE, NCPE) — analogous to EMIG's NICE/MHRA engagement in the UK.

Broad incumbents

• PhRMA (Pharmaceutical Research and Manufacturers of America): The largest US pharmaceutical industry trade association. Operates the broadest, most-resourced advocacy model globally for research-based pharma and engages FDA, CMS, and Congress. A scale-up analogue for what a highly-resourced trade association can deliver versus EMIG's UK-focused SME-leaning mandate.
• Association of the British Pharmaceutical Industry (ABPI): UK's largest pharmaceutical trade association representing large innovator pharma companies. EMIG explicitly positions itself as complementary to ABPI, and both engage DHSC, MHRA, and OLS — ABPI co-chairs the £400m Investment Facility Fund with OLS alongside EMIG's involvement. Directly comparable as a UK pharma industry body, but with a broader, larger-pharma focus.

Direct peers

• European Confederation of Pharmaceutical Entrepreneurs (EUCOPE): European trade association for small and mid-sized pharma and biotech companies. EMIG's Chairman Leslie Galloway serves as Vice President on EUCOPE's board, making this both a partner and the closest geographic peer — they share member constituencies (SME pharma/biotech) and overlapping policy agendas.
• EuropaBio: European biotech industry association based in Brussels. Comparable as a European-level trade body serving biotech and life sciences companies on EU regulatory and policy issues — overlapping constituency and policy territory with EUCOPE and EMIG's European-facing work.
• PAGB (Proprietary Association of Great Britain): UK trade association representing manufacturers of consumer healthcare products (OTC medicines, self-care). Operates a similar membership and advocacy model targeting MHRA and DHSC, and overlaps with EMIG on consumer/regulatory affairs within the UK life sciences ecosystem.
• BioIndustry Association (BIA): UK trade association representing the biotech and life sciences sector, focused on innovative R&D-intensive companies. Overlaps with EMIG's life sciences remit, particularly on regulatory and market access issues for smaller UK innovators; serves a similar member base of UK-based life sciences companies.
• Association of Medical Research Charities (AMRC): UK membership body for medical research charities. AMRC is listed as a free-tier EMIG member and works in adjacent life sciences policy territory (research funding, clinical trials, patient access), making it a complementary rather than competitive peer with overlapping stakeholder engagement.
• British Generic Manufacturers Association (BGMA): UK trade body representing generic medicines manufacturers. Comparable as a UK-focused pharma trade association engaging the same DHSC, MHRA, and NHS stakeholders on pricing, supply, and market access — areas where EMIG's Market Access SIG also operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ethicalmedicine
• LinkedInlinkedin.com/company/emig-ethical-medicines-industry-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ethical Medicines Industry Group